---
document_datetime: 2026-02-05 14:25:31
document_pages: 18
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/clopidogrel-zentiva-h-c-000975-ii-0092-epar-assessment-report_en.pdf
document_name: clopidogrel-zentiva-h-c-000975-ii-0092-epar-assessment-report_en.pdf
version: success
processing_time: 7.2265947
conversion_datetime: 2026-02-09 22:07:11.3861
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

17 July 2025 EMA/235458/2025 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Clopidogrel Zentiva

International non-proprietary name: Clopidogrel

Procedure No. EMEA/H/C/000975/II/0092

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure.............................................. 4                                 |
|----------------------------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation................................................................................................ 4   |
| 1.2. Steps taken for the assessment of the product....................................................... 4                |
| 2. Scientific discussion................................................................................ 5                 |
| 2.1.1. About the product ........................................................................................... 5     |
| 2.2. Non-clinical aspects............................................................................................ 6    |
| 2.2.1. Ecotoxicity/environmental risk assessment ......................................................... 6               |
| 2.2.2. Discussion on non-clinical aspects ..................................................................... 7          |
| 2.2.3. Conclusion on the non-clinical aspects................................................................ 8            |
| 2.3. Clinical aspects.................................................................................................. 8  |
| 2.3.1. Introduction ................................................................................................... 8  |
| 2.4. Clinical efficacy.................................................................................................. 8 |
| 2.4.1. Main study(ies)............................................................................................... 8    |
| 2.4.2. Discussion and conclusion on clinical efficacy.....................................................10               |
| 2.5. Clinical safety...................................................................................................11  |
| 2.5.1. Discussion on clinical safety.............................................................................12        |
| 2.5.2. Conclusions on clinical safety ...........................................................................12        |
| 2.5.3. PSUR cycle....................................................................................................13    |
| 2.6. Risk management plan ......................................................................................13         |
| 2.7. Update of the Product information.......................................................................13            |
| 2.7.1. User consultation ...........................................................................................15     |
| 3. Benefit-Risk Balance ............................................................................. 16                   |
| 3.1. Conclusions......................................................................................................16   |
| 4. Recommendations................................................................................. 17                     |
| 5. EPAR changes ....................................................................................... 18                 |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

CI Confidence Interval TIA Transient Ischemic Attack PCI Percutaneous Coronary Intervention MI Myocardial infarction STEMI  ST segment elevation acute myocardial infarction CABG   Coronary artery bypass graft surgery DAPT Dual antiplatelet therapy mg Milligram SmPC   Summary of Product Characteristics

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Zentiva k.s. submitted to the European Medicines Agency on 5 December 2024 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include, in combination with acetylsalicylic acid (ASA), patients with ST segment elevation acute myocardial infarction (STEMI) who are undergoing percutaneous coronary intervention (PCI) for CLOPIDOGREL ZENTIVA. As a consequence, sections 4.1, 4.2, 4.4 and 5.1 of the SmPC are updated. Version 0.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet, introduce minor editorial changes to the PI and bring it in line with the latest QRD template version 10.4.

## Information on paediatric requirements

Not applicable

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Fátima Ventura

Co-Rapporteur:

N/A

| Timetable           | Actual dates    |
|---------------------|-----------------|
| Submission date     | 5 December 2024 |
| Start of procedure: | 26 January 2025 |

<div style=\"page-break-after: always\"></div>

| Timetable                                            | Actual dates   |
|------------------------------------------------------|----------------|
| CHMP Rapporteur Assessment Report                    | 22 March 2025  |
| PRAC Rapporteur Assessment Report                    | 22 March 2025  |
| PRAC members comments                                | 3 April 2025   |
| PRAC Outcome                                         | 10 April 2025  |
| CHMP members comments                                | 11 April 2025  |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 18 April 2025  |
| Request for supplementary information (RSI)          | 25 April 2025  |
| CHMP Rapporteur Assessment Report                    | 30 June 2025   |
| PRAC Rapporteur Assessment Report                    | 27 June 2025   |
| PRAC members comments                                | 1 July 2025    |
| Updated PRAC Rapporteur Assessment Report            | 3 July 2025    |
| PRAC Outcome                                         | 10 July 2025   |
| CHMP members comments                                | 14 July 2025   |
| Updated CHMP Rapporteur Assessment Report            | 17 July 2025   |
| Opinion                                              | 24 July 2025   |

## 2. Scientific discussion

## Introduction

This is an extension of indication to include the use of clopidogrel in combination with acetylsalicylic acid (ASA), in patients with ST segment elevation acute myocardial infarction (STEMI) who are undergoing percutaneous coronary intervention (PCI) for CLOPIDOGREL ZENTIVA.

Sections 4.1, 4.2, 4.4 and 5.1 of the SmPC were updated. Version 0.1 of the RMP has also been submitted.

## 2.1.1. About the product

Clopidogrel Zentiva is an antithrombotic agents authorised in the following indications:

Secondary prevention of atherothrombotic events

Clopidogrel is indicated in:

- adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;
- adult patients suffering from acute coronary syndrome:
- o non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following

<div style=\"page-break-after: always\"></div>

percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);

- o ST-segment-elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

Prevention of atherothrombotic and thromboembolic events in atrial fibrillation

In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

An ERA report was submitted to consider the environmental risk of Clopidogrel Zentiva, 75 mg and 300mg, film-coated tablets, a variation II/C.I.6.a. This concerns an extension of indication to include clopidogrel in combination with acetylsalicylic acid in ST-segment elevation acute myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI).

Table 1- Summary of main study results for Clopidogrel

| Substance (INN/Invented Name): Clopidogrel Zentiva               | Substance (INN/Invented Name): Clopidogrel Zentiva   | Substance (INN/Invented Name): Clopidogrel Zentiva   | Substance (INN/Invented Name): Clopidogrel Zentiva   |
|------------------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| CAS-number (if available):                                       | CAS-number (if available):                           | CAS-number (if available):                           | CAS-number (if available):                           |
| PBT screening                                                    |                                                      | Result                                               | Conclusion                                           |
| Bioaccumulation potential- log K ow                              | OECD107                                              | 4.15                                                 | Potential PBT N                                      |
| PBT-assessment                                                   | PBT-assessment                                       | PBT-assessment                                       | PBT-assessment                                       |
| Parameter                                                        | Result relevant for conclusion                       |                                                      | Conclusion                                           |
| Bioaccumulation                                                  | log K ow                                             | 4.15                                                 | not B                                                |
| PBT-statement:                                                   | The compound is not considered as PBT nor vPvB       | The compound is not considered as PBT nor vPvB       | The compound is not considered as PBT nor vPvB       |
| Phase I                                                          | Phase I                                              | Phase I                                              | Phase I                                              |
| Calculation                                                      | Value                                                | Unit                                                 | Conclusion                                           |
| PEC surface water                                                | 0.375                                                | μ g/L                                                | > 0.01 threshold Y                                   |
| Other concerns (e.g., chemical class)                            |                                                      |                                                      | N                                                    |
| Phase II Physical-chemical properties and fate                   | Phase II Physical-chemical properties and fate       | Phase II Physical-chemical properties and fate       | Phase II Physical-chemical properties and fate       |
| Study type                                                       | Test protocol                                        | Results                                              | Remarks                                              |
| Adsorption-Desorption                                            | OECD 106                                             | log Koc= 5.17                                        |                                                      |
| Aerobic and Anaerobic Transformation in Aquatic Sediment Systems | OECD 308                                             | DT50total system = 7.5 (sediment 1) -13.5            |                                                      |

<div style=\"page-break-after: always\"></div>

|                                               |                          | (sediment 2) days; DT50water =7.2(sediment 1 8.1 (sediment 2) days. At the end of the study, there was no parent compound remaining in the total system (in 104 days). Day 104: Water layer: parent   | (sediment 2) days; DT50water =7.2(sediment 1 8.1 (sediment 2) days. At the end of the study, there was no parent compound remaining in the total system (in 104 days). Day 104: Water layer: parent   | (sediment 2) days; DT50water =7.2(sediment 1 8.1 (sediment 2) days. At the end of the study, there was no parent compound remaining in the total system (in 104 days). Day 104: Water layer: parent   |                                 |
|-----------------------------------------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| Phase IIa Effect studies                      | Phase IIa Effect studies | Phase IIa Effect studies                                                                                                                                                                              | Phase IIa Effect studies                                                                                                                                                                              | Phase IIa Effect studies                                                                                                                                                                              | Phase IIa Effect studies        |
| Study type                                    | Test protocol            | Endpoint                                                                                                                                                                                              | value                                                                                                                                                                                                 | Unit                                                                                                                                                                                                  | Remarks                         |
| Algae, Growth Inhibition Test/ Species        | OECD 201                 | NOEC                                                                                                                                                                                                  | 850                                                                                                                                                                                                   | µg/L                                                                                                                                                                                                  | Pseudokirchneriella subcapitata |
| Daphnia sp . Reproduction Test                | OECD 211                 | NOEC                                                                                                                                                                                                  | 710                                                                                                                                                                                                   | µg/L                                                                                                                                                                                                  | Daphnia magna                   |
| Fish, Early Life Stage Toxicity Test/ Species | OECD 210                 | NOEC                                                                                                                                                                                                  | 310                                                                                                                                                                                                   | µg/L                                                                                                                                                                                                  | Pimephales promelas             |
| Activated Sludge, Respiration Inhibition Test | OECD 209                 | EC                                                                                                                                                                                                    |                                                                                                                                                                                                       | µg/L                                                                                                                                                                                                  |                                 |

Phase I: The shake flask method (OECD test 107) was used to determine the LogKow value of 4.15, which is below the trigger value of 4.5, for further screening of persistence, bioaccumulation, and toxicity (PBT). The log Kow reaches the threshold values for assessing secondary poisoning (Log Kow ≥ 3). However, since  an  existing  ERA  was  deemed  satisfactory  by  a  competent  EU  authority,  repeating  studies  is  not considered required, in accordance with 3Rs principle by the EMA guideline EMEA/CHMP/SWP/4447/00 Rev. 1, 2024. . In the context of the obligation of the MAH to take due account of technical and scientific progress, the CHMP recommends that if the Applicant has a letter of access, they should provide the available results from previously referenced study reports in approved products, as well as the study reports. In the absence of data sharing, the applicant should confirm that the scientific conclusions of the previous ERA remain applicable.

The estimated PECsurface water for clopidogrel is 0.375 µg/L, far above the action limit of 0.01 µg/L, as defined in the Guideline EMEA/CHMP/SWP/4447/00. Clopidogrel is degraded in the environment, has low potential for bioaccumulation (Log KOC = 5.17) and exhibits moderate chronic toxicity. The substance has a PEC/PNEC ratio of less than 1, indicating that the risk is negligible and that it poses an insignificant environmental risk.

The precautionary and safety measures taken, including the general statement in the SmPC and PL have been applied to reduce any risk to the environment.

## 2.2.2. Discussion on non-clinical aspects

According to the Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use, EMEA/CHMP/SWP/4447/00,  Rev1,  2024,  an  Environmental  Risk  Assessment  (ERA)  should  have  been submitted irrespective of the legal status basis.

<div style=\"page-break-after: always\"></div>

## 2.2.3. Conclusion on the non-clinical aspects

The MAH submitted an updated Phase II ERA following the Guideline EMEA/CHMP/SWP/4447/00 Rev.1, 2024.

The log Kow reaches the threshold values for assessing secondary poisoning (Log Kow ≥ 3). However, since  an  existing  ERA  was  deemed  satisfactory  by  a  competent  EU  authority,  repeating  studies  is  not considered required, in accordance with 3Rs principle by the EMA guideline EMEA/CHMP/SWP/4447/00 Rev. 1, 2024. In the context of the obligation of the MAH to take due account of technical and scientific progress, the CHMP recommends that if the Applicant has a letter of access, they should provide the available results from previously referenced study reports in approved products, as well as the study reports. In the absence of data sharing, the applicant should confirm that the scientific conclusions of the previous ERA remain applicable.

## 2.3. Clinical aspects

## 2.3.1. Introduction

The MAH has submitted literature to support the extension of indication.

## 2.4. Clinical efficacy

## 2.4.1. Main study(ies)

## PCI-Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY) study

This was a prospectively planned analysis of the 1863 patients undergoing PCI after mandated angiography in CLARITY-Thrombolysis in Myocardial Infarction (TIMI), a randomized, double-blind, placebo-controlled trial of clopidogrel in patients receiving fibrinolytics for STEMI.

Patients received aspirin and were randomized to receive either clopidogrel (300 mg loading dose, then 75 mg once daily) or placebo, initiated with fibrinolysis, and given until coronary angiography, which was performed 2 to 8 days after initiation of the study drug. For patients undergoing coronary artery stenting, it was recommended the administration of the open-label clopidogrel (including a loading dose) after the diagnostic angiogram.

The primary efficacy outcome for this analysis was the composite of cardiovascular death, recurrent MI, or stroke from PCI to 30 days after randomization. Secondary outcomes included recurrent MI or stroke before PCI and the composite of cardiovascular death, recurrent MI, or stroke from randomization to 30 days. Clopidogrel pretreatment  significantly reduced  the  incidence of cardiovascular death  or ischemic complications both before and after PCI and without a significant increase in major or minor bleeding.

## Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events-Seventh Organization to Assess Strategies in Ischemic Syndromes (CURRENT-OASIS 7) trial

This trial was designed to determine whether a doubling of the loading and initial maintenance doses of clopidogrel was superior to the standard-dose regimen and whether higher-dose aspirin (300 to 325 mg daily) was superior to lower-dose aspirin (75 to 100 mg daily) in patients with acute coronary syndromes referred for an early invasive strategy.

<div style=\"page-break-after: always\"></div>

The primary outcome was the time to cardiovascular death, myocardial infarction, or stroke, whichever occurred first, up to day 30. The secondary outcomes included the composite of death from cardiovascular causes,  myocardial  infarction,  stroke,  or  recurrent  ischemia;  the  individual  components  of  the  primary outcome; and death from any cause. Definite or probable stent thrombosis, as defined by the Academic Research Consortium was a prespecified secondary outcome in the subgroup of patients who underwent PCI.

A  nominally  significant  reduction  in  the  primary  outcome  was  associated  with  the  use  of  higher-dose clopidogrel in the subgroup of 17,263 study participants who underwent PCI after randomization (69%). Double-dose  clopidogrel  significantly  reduced  the  secondary  outcome  of  stent  thrombosis,  including angiographically confirmed definite stent thrombosis, in the subgroup of patients who underwent PCI.

## The Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty - Myocardial Infarction (ARMYDA-6 MI)

The purpose of this study was to compare 600- and 300-mg clopidogrel loading doses in patients with STEMI.

A total of 201 patients undergoing primary PCI for STEMI randomly received a 600-mg (n = 103) or 300mg (n = 98) clopidogrel loading dose before the procedure. The primary endpoint was the evaluation of the infarct size, defined as the area under the curve of cardiac markers.

The following secondary endpoints were investigated: Prevalence of Thrombolysis In Myocardial Infarction (TIMI) flow &gt;grade 1 at the diagnostic coronary angiography before PCI and of TIMI flow grade &lt;3 after PCI,  Left  ventricular  ejection  fraction  by  transthoracic  echocardiography  at  discharge,  The  incidence  of major adverse cardiovascular events (MACEs), Occurrence of bleeding/entry site complications.

In STEMI patients, pre-treatment with a 600-mg clopidogrel loading dose before primary PCI was associated with a reduction of the infarct size compared with a 300-mg loading dose, as well as with improvement of angiographic results, residual cardiac function, and 30-day major adverse cardiovascular events.

## Harmonizing  Outcomes  With  Revascularization  and  Stents  in  Acute  Myocardial  Infarction (HORIZONS-AMI)

In this trial, 3,602 patients with STEMI undergoing primary PCI were randomized to bivalirudin (n = 1,800) or unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor (n = 1,802). Randomization was stratified by  thienopyridine  loading  dose,  which  was  determined  before  random  assignment.  The  primary randomization was stratified by whether the patient was to be loaded with 300 mg of clopidogrel, 600 mg of clopidogrel, or 500 mg of ticlopidine before catheterization.

Subgroup analyses of 300 versus 600 mg of clopidogrel was performed. The aim was to determine whether a  600-mg  loading  dose  of  clopidogrel  compared  with  300  mg  results  in  improved  clinical  outcomes  in patients with STEMI undergoing PCI.

The 30-day rates of mortality, reinfarction, MACE, and non- CABG-related major bleeding were significantly lower in the 600-mg clopidogrel loading dose group compared with the 300-mg loading dose group. The incidence of acquired thrombocytopenia was similar between the 2 groups. Among patients treated with PCI and coronary stent implantation, definite or probable stent thrombosis was also significantly lower among patients in the 600-mg compared with the 300-mg loading dose group.

## Clopidogrel for the Reduction of Events During Observation (CREDO) trial

This study was conducted to evaluate the benefit of long-term (12-month) treatment with clopidogrel after PCI and to determine the benefit of initiating clopidogrel with a pre-procedure loading dose, both in addition to aspirin therapy.

<div style=\"page-break-after: always\"></div>

The primary 1-year outcome was the composite of death, MI, and stroke in the intent-to-treat population. Prespecified  secondary  analyses  included  the  individual  components  of  the  composite  end  points, administration of clopidogrel less than 6 hours or at least 6 hours before PCI, and the need for target vessel revascularization or any revascularization at 1 year.

The results indicate that in patients undergoing PCI, the continuation of clopidogrel and aspirin therapy for 1 year led to a significant reduction in atherothrombotic events compared with treatment for only 4 weeks. Although a 300-mg loading dose of clopidogrel administered more than 3 hours prior to the procedure was not significantly  better  than  administration  of  clopidogrel  without  a  loading  dose  immediately  after  the procedure, the subgroup analysis of patients treated at least 6 hours prior to PCI suggested a significant reduction in periprocedural major adverse cardiac events, with or without the concomitant use of a GpIIbIIIa antagonist.

## Efficacy  of  Xience/Promus  Versus  Cypher  to  Reduce  Late  Loss  After  Stenting  (EXCELLENT) Randomized, Multicenter Study

This study aimed to study whether 6-month DAPT would be noninferior to 12-month DAPT after implantation of drug-eluting stents.

The  primary  end  point  was  target  vessel  failure  defined  as  a  composite  of  cardiac  death,  myocardial infarction, or target vessel revascularization during the 12-month period after randomization. Secondary end points included the individual components of the primary endpoint; death resulting from any cause; death  or  myocardial  infarction;  stent  thrombosis;  major  bleeding  according  to  the  Thrombolysis  in Myocardial  Infarction  criteria;  major  adverse  cardiocerebral  events,  which  were  a  composite  of  death, myocardial infarction, stroke, or any revascularization; and a safety end point, which was a composite of death,  myocardial  infarction,  stroke,  stent  thrombosis,  or  Thrombolysis  in  Myocardial  Infarction  major bleeding.

The trial showed that the rate of target vessel failure was not significantly different between the 6- and 12month DAPT groups after PCI with drug-eluting stents and that 6-month DAPT was noninferior to 12-month DAPT in the risk of target vessel failure.

## 2.4.2. Discussion and conclusion on clinical efficacy

Clopidogrel pretreatment  significantly reduced  the  incidence of cardiovascular death  or ischemic complications both before and after PCI and without a significant increase in major or minor bleeding.

Double-dose  clopidogrel  significantly  reduced  the  secondary  outcome  of  stent  thrombosis,  including angiographically confirmed definite stent thrombosis, in the subgroup of patients who underwent PCI.

In STEMI patients, pre-treatment with a 600-mg clopidogrel loading dose before primary PCI was associated with a reduction of the infarct size compared with a 300-mg loading dose, as well as with improvement of angiographic results, residual cardiac function, and 30-day major adverse cardiovascular events.

The 30-day rates of mortality, reinfarction, MACE, and non- CABG-related major bleeding were significantly lower in the 600-mg clopidogrel loading dose group compared with the 300-mg loading dose group. The incidence of acquired thrombocytopenia was similar between the 2 groups. Among patients treated with PCI and coronary stent implantation, definite or probable stent thrombosis was also significantly lower among patients in the 600-mg compared with the 300-mg loading dose group.

<div style=\"page-break-after: always\"></div>

In patients undergoing PCI, the continuation of clopidogrel and aspirin therapy for 1 year led to a significant reduction  in  atherothrombotic  events  compared  with  treatment  for  only  4  weeks.  Although  a  300-mg loading dose of clopidogrel administered more than 3 hours prior to the procedure was not significantly better  than  administration  of  clopidogrel  without  a  loading  dose  immediately  after  the  procedure,  the subgroup analysis of patients treated at least 6 hours prior to PCI suggested a significant reduction in periprocedural  major  adverse  cardiac  events,  with  or  without  the  concomitant  use  of  a  GpIIb-IIIa antagonist.

The rate of target vessel failure was not significantly different between the 6- and 12-month DAPT groups after PCI with drug-eluting stents and that 6-month DAPT was noninferior to 12-month DAPT in the risk of target vessel failure.

No issues are raised regarding clinical efficacy.

## 2.5. Clinical safety

In the CLARITY study, there was no significant excess in the rates of TIMI major bleeding (0.5% vs 1.1%), TIMI minor bleeding (1.4% vs 0.8%), or the combination (2.0% vs 1.9%) following PCI in those who received  clopidogrel  pretreatment  compared  with  those  who  did  not.  In  addition,  among  patients  who received a GpIIb/IIIa inhibitor during PCI, the rate of TIMI major or minor bleeding was no higher in those who had received clopidogrel pretreatment (2.1% [6/283]) than in those who did not receive pretreatment (2.9% [9/307]) (P=0.36). Eligible trial participants were between 18 and 75 years old. No patients above 75 years were included.

In the CURRENT-OASIS 7 trial, major bleeding occurred in 2.5% of patients in the double-dose clopidogrel group as compared with 2.0% of patients in the standard-dose clopidogrel group (hazard ratio, 1.24;95% CI, 1.05 to 1.46; P = 0.01). The incidence of major bleeding as defined according to the TIMI criteria and the incidence of severe bleeding were also higher among patients who received double dose clopidogrel. The increased incidences of major and severe bleeding were accounted for mainly by a higher rate of redcell  transfusion  among  patients  in  the  double  dose  group.  The  use  of  double-dose  clopidogrel  did  not increase the incidence of fatal or intracranial bleeding, nor did it significantly increase the incidence of bleeding  that  was  related  to  Coronary  artery  bypass  graft  surgery  (CABG).  There  were  no  reports  of neutropenia in either clopidogrel group. In this trial, 26% of patients included were older than 75 years.

In the ARMYDA-6 MI study, the safety endpoints did not differ in the 600- and 300-mg arms: major bleeding at 1 month occurred in 1.9% versus 2.0% of patients, nonentry site minor bleeding in 7.8% versus 6.1%, and entry site complications in 2.9% versus 3.1%. No patient had post-procedure thrombocytopenia with platelet  count  less  than  70x10 9 /L.  Detailed  age  characteristics  of  participants  are  not  available  in  the published article.

In the HORIZONS-AMI study, the 600-mg loading dose was not associated with increased rates of major bleeding or thrombocytopenia. Overall adverse event rates were lower after a 600-mg loading dose than a 300-mg loading dose with both anticoagulation regimens. No patients above 75 years of age were included in the trial. The 30-day rates of mortality, reinfarction, MACE, and non- CABG-related major bleeding were significantly lower in the 600-mg clopidogrel loading dose group compared with the 300-mg loading dose group. The incidence of acquired thrombocytopenia was similar between the 2 groups. Among patients treated  with  PCI  and  coronary  stent  implantation,  definite  or  probable  stent  thrombosis  was  also significantly lower among patient in the 600-mg compared with the 300-mg loading dose group.

In  the  CREDO  trial,  clopidogrel  pretreatment  at  28  days  did  not  significantly  increase  major  or  minor bleeding. Minor bleeding increased non-significantly in patients who also received a GpIIb-IIIa antagonist

<div style=\"page-break-after: always\"></div>

(2.8%  pretreatment  vs  1.0%  no  pretreatment;  P=0.08).  Importantly,  there  were  no  fatal  bleeds  or intracranial  haemorrhages.  Nearly  all  major  bleeding  events  were  associated  with  invasive  procedures (either the index PCI or CABG) in both groups. Patients treated with clopidogrel for 1 year experienced a trend toward an increase in major bleeding (8.8% clopidogrel vs 6.7% placebo; P=0.07). Approximately two thirds of all major bleeds occurred in patients undergoing CABG, with all such patients experiencing a high incidence of major bleed. No patients above 75 years of age were included in the study.

In the EXCELLENT study, there was no difference in safety outcome ( composite of death, MI, stroke, stent thrombosis or TIMI major bleeding) between the arms 6 months DAPT and 12 months DAPT. No patients above 75 years of age were included in the study.

## 2.5.1. Discussion on clinical safety

In the studies that were presented which did not include patients older than 75 years-old, the 600-mg loading  dose  was  not  associated  with  increased  rates  of  major  bleeding  or  thrombocytopenia  when compared to the 300 mg loading dose.

In the CURRENT-OASIS 7 trial that included patients older than 75 years-old although there is no specific information regarding safety in this age group, major bleeding occurred in 2.5% of patients in the doubledose clopidogrel group as compared with 2.0% of patients in the standard-dose clopidogrel group (hazard ratio, 1.24;95% CI, 1.05 to 1.46; P = 0.01). The incidence of major bleeding as defined according to the TIMI criteria and the incidence of severe bleeding were also higher among patients who received double dose clopidogrel. The increased incidences of major and severe bleeding were accounted for mainly by a higher  rate  of  red-cell  transfusion  among  patients  in  the  double  dose  group.  The  use  of  double-dose clopidogrel did not increase the incidence of fatal or intracranial bleeding, nor did it significantly increase the  incidence  of  bleeding  that  was  related  to  CABG.  There  were  no  reports  of  neutropenia  in  either clopidogrel group.

Due to the limited clinical data in patients ≥75 years old with STEMI PCI, and increased risk of bleeding, the use of clopidogrel 600 mg loading dose should be considered only after an individual assessment of the bleeding  risk  of  the  patient  by  the  physician,  The  RMP  includes  a  targeted  follow-up  questionnaire  for intracranial/intracerebral haemorrhage in very elderly (&gt;75-year-old) patients

## 2.5.2. Conclusions on clinical safety

In the majority of studies that were presented, the 600-mg loading dose was not associated with increased rates of major bleeding or thrombocytopenia when compared to the 300 mg loading dose. In the CURRENT - OASIS 7 trial, that included patients older than 75 years-old, although there is no specific information regarding safety in this age group, double-dose clopidogrel group was associated with an increased risk of major bleeding. Nevertheless, the use of double-dose clopidogrel did not increase the incidence of fatal or intracranial bleeding, nor did it significantly increase the incidence of bleeding that was related to CABG.

Due to the limited clinical data in patients ≥75 years old with STEMI PCI, and increased risk of bleeding, the use of clopidogrel 600 mg loading dose should be considered only after an individual assessment of the bleeding  risk  of  the  patient  by  the  physician,  The  RMP  includes  a  targeted  follow-up  questionnaire  for intracranial/intracerebral haemorrhage in very elderly (&gt;75-year-old) patients.

<div style=\"page-break-after: always\"></div>

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The CHMP endorsed the Risk Management Plan version 0.3 with the following content:

## Safety concerns

The MAH submitted an RMP version with this application (version 0.1 with DLP 1 August 2024).

The MAH has provided the first version of the RMP in this variation for extension of indication.

## Safety Specification and Safety Concerns

TableSvlll.1:Summaryofsafetyconcerns

| Summaryofsafetyconcerns   |                              |
|---------------------------|------------------------------|
| Importantidentifiedrisks  | Majorbleeding(includingICHa) |
| Importantpotentialrisks   | None                         |
| Missinginformation        | None                         |

## Pharmacovigilance plan

Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:

Specific adverse reaction follow-up questionnaire for:

- Major bleeding (including ICH)

Additional pharmacovigilance activities: Not applicable.

## Risk minimisation measures

The safety information in the proposed product information is aligned to the reference medicinal product.

The MAH has proposed routine risk minimisation measures, which are in line with the reference medicinal product. This is endorsed.

## 2.7. Update of the Product information

## Secondary prevention of atherothrombotic events

## Section 4.1

Clopidogrel is indicated in:

<div style=\"page-break-after: always\"></div>

## 4.2

In patients suffering from acute coronary syndrome:

• ST segment elevation acute myocardial infarction:

-For medically treated patients eligible for thrombolytic/fibrinolytic therapy clopidogrel should be given as a single daily dose of 75 mg initiated with a 300 mg loading dose in combination with ASA and with or without thrombolytics. For medically treated patients over 75 years of age clopidogrel should be initiated without a loading dose. Combined therapy should be started as early as possible after symptoms start and continued for at least four weeks.

The benefit of the combination of clopidogrel with ASA beyond four weeks has not been studied in this setting (see section 5.1).

## -When percutaneous coronary intervention (PCI) is intended:

- Clopidogrel  should  be  initiated  at  a  loading  dose  of  600  mg  in  patients  undergoing primary PCI and in patients undergoing PCI more than 24 hours of receiving fibrinolytic therapy. In patients ≥ 75 years old the 600 mg LD should be administered with caution (see section 4.4).
- Clopidogrel 300 mg loading dose should be given in patients undergoing PCI within 24 hours of receiving fibrinolytic therapy.
- Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
- Adult patients suffering from acute coronary syndrome:
- -Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
- -ST segment elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/ fibrinolytic therapy.

In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)

Clopidogrel in combination with ASA is indicated in:

- Adult patients with moderate to high-risk TIA (ABCD2 score ≥ 4) or minor IS (NIHSS ≤ 3) within 24 hours of either the TIA or IS event.

Prevention of atherothrombotic and thromboembolic events in atrial fibrillation

In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.

For further information please refer to section 5.1.

<div style=\"page-break-after: always\"></div>

## Clopidogrel treatment should be continued at 75 mg once a day with ASA 75 mg - 100 mg daily. Combined therapy should be started as early as possible after symptoms start and continued up to 12 months (see section 5.1).

Adult patients with moderate to high-risk TIA or minor IS:

Adult patients with moderate to highrisk TIA (ABCD2 score ≥4) or minor IS (NIHSS ≤3) should be given a loading dose of clopidogrel 300 mg followed by clopidogrel 75 mg once daily and ASA (75 mg -100 mg once daily). Treatment with clopidogrel and ASA should be started within 24 hours of the event and be continued for 21 days followed by single antiplatelet therapy.

In patients with atrial fibrillation, clopidogrel should be given as a single daily dose of 75 mg. ASA (75 100 mg daily) should be initiated and continued in combination with clopidogrel (see section 5.1).

If a dose is missed:

· Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time.

· For more than 12 hours: patients should take the next dose at the regular scheduled time and should not double the dose.

## Special populations

## Elderly patients

Non-ST  segment  elevation acute coronary syndrome  (unstable  angina or  non-Qwave myocardial infarction):

· A 600 mg loading dose may be considered in patients &lt;75 years of age when percutaneous coronary intervention is intended (see section 4.4).

ST segment elevation acute myocardial infarction:

· For medically treated patients eligible for thrombolytic/fibrinolytic therapy: in patients over 75 years of age clopidogrel should be initiated without a loading dose.

For patients undergoing primary PCI and in patients undergoing PCI more than 24 hours of receiving fibrinolytic therapy:

· In patients ≥ 75 years old the 600 mg LD should be administered with caution (see section 4.4).

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet, introduce minor editorial changes to the PI and bring it in line with the latest QRD template version 10.4.

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons: the current update has no impact on the product information leaflet.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

Clopidogrel pretreatment  significantly reduced  the  incidence of cardiovascular death  or ischemic complications both before and after PCI and without a significant increase in major or minor bleeding.

Double-dose  clopidogrel  significantly  reduced  the  secondary  outcome  of  stent  thrombosis,  including angiographically confirmed definite stent thrombosis, in the subgroup of patients who underwent PCI.

In STEMI patients, pre-treatment with a 600-mg clopidogrel loading dose before primary PCI was associated with a reduction of the infarct size compared with a 300-mg loading dose, as well as with improvement of angiographic results, residual cardiac function, and 30-day major adverse cardiovascular events.

The 30-day rates of mortality, reinfarction, MACE, and non- CABG-related major bleeding were significantly lower in the 600-mg clopidogrel loading dose group compared with the 300-mg loading dose group. The incidence of acquired thrombocytopenia was similar between the 2 groups. Among patients treated with PCI and coronary stent implantation, definite or probable stent thrombosis was also significantly lower among patients in the 600-mg compared with the 300-mg loading dose group.

In patients undergoing PCI, the continuation of clopidogrel and aspirin therapy for 1 year led to a significant reduction  in  atherothrombotic  events  compared  with  treatment  for  only  4  weeks.  Although  a  300-mg loading dose of clopidogrel administered more than 3 hours prior to the procedure was not significantly better  than  administration  of  clopidogrel  without  a  loading  dose  immediately  after  the  procedure,  the subgroup analysis of patients treated at least 6 hours prior to PCI suggested a significant reduction in periprocedural  major  adverse  cardiac  events,  with  or  without  the  concomitant  use  of  a  GpIIb-IIIa antagonist.

The rate of target vessel failure was not significantly different between the 6- and 12-month DAPT groups after PCI with drug-eluting stents and that 6-month DAPT was noninferior to 12-month DAPT in the risk of target vessel failure.

No issues are raised regarding clinical efficacy.

In the majority of studies that were presented, the 600-mg loading dose was not associated with increased rates of major bleeding or thrombocytopenia when compared to the 300 mg loading dose. In the CURRENT - OASIS 7 trial, that included patients older than 75 years-old, although there is no specific information regarding safety in this age group, double-dose clopidogrel group was associated with an increased risk of major bleeding. Nevertheless, the use of double-dose clopidogrel did not increase the incidence of fatal or intracranial bleeding, nor did it significantly increase the incidence of bleeding that was related to CABG.

Due to the limited clinical data in patients ≥75 years old with STEMI PCI, and increased risk of bleeding, the use of clopidogrel 600 mg loading dose should be considered only after an individual assessment of the bleeding  risk  of  the  patient  by  the  physician,  The  RMP  includes  a  targeted  follow-up  questionnaire  for intracranial/intracerebral haemorrhage in very elderly (&gt;75-year-old) patients.

## 3.1. Conclusions

The overall B/R of clopidogrel Zentiva in combination with acetylsalicylic acid in ST segment elevation acute myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI) considered to be positive.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include, in combination with acetylsalicylic acid (ASA), patients with ST segment elevation acute myocardial infarction (STEMI) who are undergoing percutaneous coronary intervention (PCI) for CLOPIDOGREL ZENTIVA. As a consequence, sections 4.1, 4.2, 4.4 and 5.1 of the SmPC are updated. Version 0.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet, introduce minor editorial changes to the PI and bring it in line with the latest QRD template version 10.4.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

the terms of the Marketing Authorisation, concerning the following change:

| Variation rejected   | Variation rejected                                                                                                             | Type    |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II |

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk management plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important

<div style=\"page-break-after: always\"></div>

(pharmacovigilance or risk minimisation) milestone being reached.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Product Name-H-C-Product Number-II-Var.92'

## Attachments

1. SmPC Package Leaflet (changes highlighted)